Skip to the content
ClearNote Health logologo darklogo light
  • Our Story
    • About Us
    • Leadership Team
    • FAQs
    • Careers
  • Our Approach
    • Epigenomics Platform
    • Clinical Trials
    • Publications
  • Our Products
    • Biopharma
    • Pancreatic Cancer
    • Ovarian Cancer
  • Our News
  • Contact Us
  • Order Test
Search
ClearNote Health logo
  • Our Story
    • About Us
    • Leadership Team
    • FAQs
    • Careers
  • Our Approach
    • Epigenomics Platform
    • Clinical Trials
    • Publications
  • Our Products
    • Biopharma
    • Pancreatic Cancer
    • Ovarian Cancer
  • Our News
  • Contact Us
  • Order Test
ClearNote Health logo
  • Our Story
    • About Us
    • Leadership Team
    • FAQs
    • Careers
  • Our Approach
    • Epigenomics Platform
    • Clinical Trials
    • Publications
  • Our Products
    • Biopharma
    • Pancreatic Cancer
    • Ovarian Cancer
  • Our News
  • Contact Us
  • Order Test
Home2023
Press Release

ClearNote Health Announces Collaboration with Bayer to Investigate Drug Treatment Response by Liquid Biopsy in Prostate Cancer

ClearNote Health
December 14, 2023
Event

PRECEDE – The Pancreatic Cancer Early Detection Consortium | December, 2023

cnhnewcorpdev
December 1, 2023
Event

American Pancreatic Association | December, 2023

cnhnewcorpdev
December 1, 2023
Press Release

ClearNote Health Joins the Pancreatic Cancer Early Detection (PRECEDE) Consortium in New Partnership to Reduce Cancer Mortality

ClearNote Health
November 2, 2023
Press Release

Avantect Pancreatic Cancer Test Receives CPT Code and Preliminary Payment Determination from the Centers for Medicare and Medicaid Services

ClearNote Health
September 28, 2023
Event

ClearNote Health is Attending the American Diabetes Association’s 83rd Scientific Sessions in San Diego, June 23-26

cnhnewcorpdev
June 8, 2023
Event

American Diabetes Association 83rd Scientific Sessions | June, 2023

cnhnewcorpdev
June 1, 2023
Press Release

Study Validating ClearNote Health’s Avantect Pancreatic Cancer Detection Test Published in the Journal Clinical Gastroenterology and Hepatology

ClearNote Health
May 8, 2023
Event

Society for Laboratory Automation and Screening | May 2023

cnhnewcorpdev
May 1, 2023
Event

American Association for Cancer Research | April, 2023

cnhnewcorpdev
April 1, 2023

Posts pagination

1 2

Meet Us at ASCO 2026

ClearNote Health
May 28, 2026

ClearNote Health Secures $52 Million in Series D Financing and Strengthens Leadership Team to Accelerate Growth in Early Cancer Detection

ClearNote Health
May 27, 2026

Follow us
ClearNote Health logo

Empowering early cancer detection.

Order Test
Company
  • About Us
  • Leadership Team
  • Our News
  • Careers
  • Contact Us
Solutions
  • Avantect Pancreatic Cancer Test
  • Avantect Ovarian Cancer Test
  • Virtuoso Epigenomics Platform
Stay Informed

Get the latest research and announcements from ClearNote Health. Follow us:

Important information: 
The Virtuoso platform is for research use only. Not for use in diagnostic procedures. The Avantect Pancreatic and Ovarian Cancers Tests are early detection tests. The tests do not establish a diagnosis of pancreatic cancer or ovarian cancer, respectively, and results should be considered in the context of other clinical criteria.

Cancer statistics quoted on this website are taken from the CDC and SEER websites, 2025 data.

©2026 ClearNote Health, All Rights Reserved.

Avantect and Virtuoso are trademarks of ClearNote Health. Other trademarks are the property of their respective owners.

  • Privacy Policy
  • Terms of Use
  • Billing rights & protections
  • Cookie Preferences